|
Prostate size and other neglected factors influence prostate cancer treatment satisfaction
March 20, 2008BOSTON - Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.
Outcomes after prostate surgery, external radiation or brachytherapy (radioactive 'seeds') are highly individualized and depend not only on age, but also on factors that have been previously overlooked, such as the size of the prostate and whether a man has urinary symptoms due to prostate enlargement before treatment.
Previous studies focused mostly on problems with sexuality, bowel problems and problems with urinary incontinence after prostate cancer treatment, which the study confirmed as important concerns.
But the research team from nine hospitals, led by Martin G. Sanda, MD, Director of the Prostate Care Center at Beth Israel Deaconess Medical Center and Associate Professor of Surgery at Harvard Medical School, found that other symptoms, such as frequent or weak urination, are equally as important in determining overall patient satisfaction.
While many patients and doctors have assumed that prostate cancer treatment only causes side effects and does not reduce symptoms, the study found that some men with larger prostates benefit with improved urination after surgery. However, the study of 1,201 men and 625 spouses also found that overall satisfaction with treatment was lower among African-American men, despite their having received care at the same centers as their white counterparts.
The study examined the impact of the various forms of treatment on many facets of quality of life, including not only sexual function, bowel function and urinary incontinence - but also on concerns that are common yet have been previously neglected by researchers, including weak or frequent urination due to prostate enlargement as well as a man's "vitality" or hormonal function.
"We didn't presume whether one type of side effect or another is more important - instead, we measured a broad range of side effects, and asked how those mesh together and which ones actually matter in terms of either the patient's or his partner's satisfaction with the overall cancer treatment outcome," says Sanda, adding the research found a greater level of importance than previously thought in a patient's vitality, which includes concerns expressed by patients and their partners about the patient's energy level, weight and mood.
"When the patient and doctor sit down, they need to be able to take factors like the patient's age, prostate size, and treatment nuances into consideration and decide what's right. The concept of assigning a general treatment or non-treatment based simply on someone's age and cancer severity alone is no longer valid."
Researchers found that hormonal therapy, when combined with brachytherapy or with external radiation, worsened multiple aspects of quality-of-life, and had particularly profound effects on men's vitality and sexuality. Patients receiving radioactive seed treatment experienced problems with weak or frequent urination which lasted longer and had greater effect on overall satisfaction than previously appreciated.
Some men who had their prostates removed surgically reported problems with urinary incontinence, in contrast to those who experienced long-term improvement in urinary obstruction. Nerve-sparing techniques reduced the sexual side effects of that surgical procedure but did not eliminate them.
The study was the first multi-center effort to focus on satisfaction with overall outcome of cancer care and to include partners in the evaluation. And the results found that changes in quality of life played a significant role in determining whether patients and their partners were satisfied.
In particular, black patients were less satisfied with their treatment outcome, despite having received care and the same high-volume institutions as other patients.
"When I speak with black men who have undergone treatment for prostate cancer, many express dissatisfaction with their treatment-related side effects," says J. Jacques Carter, MD, MPH, a primary care physician at BIDMC. "My sense is that they feel they were not given all of the options nor given a frank discussion about the adverse effects of the different treatment modalities."
The study also confirmed a commonly held belief that treatment-related changes in quality of life among patients had a direct effect on their partners.
"The level of spousal distress arising from a patient's symptoms after prostate cancer treatment was associated with the partner's level of satisfaction with the treatment outcome," the study declares.
"Partners matter, and satisfaction with overall outcome, from the perspective of the patient and partner, should be the bottom line in health care," says Sanda. "It's the simplest thing in the world to measure, but it's something that hasn't been done very well, particularly in cancer care."
Beth Israel Deaconess Medical Center
But the research team from nine hospitals, led by Martin G. Sanda, MD, Director of the Prostate Care Center at Beth Israel Deaconess Medical Center and Associate Professor of Surgery at Harvard Medical School, found that other symptoms, such as frequent or weak urination, are equally as important in determining overall patient satisfaction.
While many patients and doctors have assumed that prostate cancer treatment only causes side effects and does not reduce symptoms, the study found that some men with larger prostates benefit with improved urination after surgery. However, the study of 1,201 men and 625 spouses also found that overall satisfaction with treatment was lower among African-American men, despite their having received care at the same centers as their white counterparts.
The study examined the impact of the various forms of treatment on many facets of quality of life, including not only sexual function, bowel function and urinary incontinence - but also on concerns that are common yet have been previously neglected by researchers, including weak or frequent urination due to prostate enlargement as well as a man's "vitality" or hormonal function.
"We didn't presume whether one type of side effect or another is more important - instead, we measured a broad range of side effects, and asked how those mesh together and which ones actually matter in terms of either the patient's or his partner's satisfaction with the overall cancer treatment outcome," says Sanda, adding the research found a greater level of importance than previously thought in a patient's vitality, which includes concerns expressed by patients and their partners about the patient's energy level, weight and mood.
"When the patient and doctor sit down, they need to be able to take factors like the patient's age, prostate size, and treatment nuances into consideration and decide what's right. The concept of assigning a general treatment or non-treatment based simply on someone's age and cancer severity alone is no longer valid."
Researchers found that hormonal therapy, when combined with brachytherapy or with external radiation, worsened multiple aspects of quality-of-life, and had particularly profound effects on men's vitality and sexuality. Patients receiving radioactive seed treatment experienced problems with weak or frequent urination which lasted longer and had greater effect on overall satisfaction than previously appreciated.
Some men who had their prostates removed surgically reported problems with urinary incontinence, in contrast to those who experienced long-term improvement in urinary obstruction. Nerve-sparing techniques reduced the sexual side effects of that surgical procedure but did not eliminate them.
The study was the first multi-center effort to focus on satisfaction with overall outcome of cancer care and to include partners in the evaluation. And the results found that changes in quality of life played a significant role in determining whether patients and their partners were satisfied.
In particular, black patients were less satisfied with their treatment outcome, despite having received care and the same high-volume institutions as other patients.
"When I speak with black men who have undergone treatment for prostate cancer, many express dissatisfaction with their treatment-related side effects," says J. Jacques Carter, MD, MPH, a primary care physician at BIDMC. "My sense is that they feel they were not given all of the options nor given a frank discussion about the adverse effects of the different treatment modalities."
The study also confirmed a commonly held belief that treatment-related changes in quality of life among patients had a direct effect on their partners.
"The level of spousal distress arising from a patient's symptoms after prostate cancer treatment was associated with the partner's level of satisfaction with the treatment outcome," the study declares.
"Partners matter, and satisfaction with overall outcome, from the perspective of the patient and partner, should be the bottom line in health care," says Sanda. "It's the simplest thing in the world to measure, but it's something that hasn't been done very well, particularly in cancer care."
Beth Israel Deaconess Medical Center
Prostate Cancer News and Current Prostate Cancer Events RSSElevated biomarkers predict risk for prostate cancer recurrence
A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.
Researchers identify promising cancer drug target in prostate tumors
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
Certain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis.
Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis
Cancer patients with low socioeconomic status (SES) have more advanced cancers at diagnosis, receive less aggressive treatment, and have a higher risk of dying in the five years following cancer diagnosis, according to a new study.
UT Southwestern urologists identify seven biomarkers that may help pinpoint prostate cancer recurrence
A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.
Radiation therapy prolongs life in men with recurrent prostate cancer
Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence.
OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer
In a multi-site study, Oregon Health & Science University Cancer Institute researchers have found that a drug called Ipilimumab, also known as MDX-010, works to stimulate the body's own immune system to fight prostate cancer. The drug was found to be effective in study participants with a serious type of prostate cancer - one where the tumor has spread and was resistant to hormonal treatment and, in some cases, also to chemotherapy.
OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer
Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.
How advanced prostate cancer becomes resistant to androgen-deprivation therapy
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy.
Certain form of tomatoes could be key to prostate cancer prevention
New cancer research from the University of Missouri suggests that eating a certain form of tomato product could be the key to unlocking the prostate cancer-fighting potential of the tomato.
More Prostate Cancer News Articles
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh, Janet Farrar Worthington |
 | The Vitamin D Cure by James Dowd, Diane Stafford |
 | Prostate Health in 90 Days by Larry Clapp |
 | You Can Beat Prostate Cancer by Robert J. Marckini |
 | A Primer on Prostate Cancer: The Empowered Patient's Guide by Stephen Strum, Donna L. Pogliano |
 | The Natural Prostate Cure by Roger Mason |
 | Prostate And Cancer: A Family Guide To Diagnosis, Treatment And Survival (3rd Edition) by Sheldon Marks |
 | Biopsy Interpretation of the Prostate (Biopsy Interpretation Series) by Jonathan I Epstein, George J Netto |
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer by Patrick C. Walsh, Janet Farrar Worthington |
 | Eat to Beat Prostate Cancer Cookbook by David Ricketts |
| © 2008 BrightSurf.com |